WNBA Superstar Brittney Griner Detained in Russia over Alleged Cannabis Possession

When Chris Faraone learned that petition circulators were gathering signatures outside Massachusetts retailers to put recreational cannabis back on the ballot, he decided to investigate.

Outside a Trader Joe's in Hanover and a Walmart in Weymouth, the veteran journalist and editor of Talking Joints Memo encountered what he believed were misleading explanations of a proposal that could dismantle the state's regulated adult-use cannabis market.

One circulator, according to footage in Faraone's forthcoming documentary, Just Say No!, described the petition as an opportunity to put marijuana back before voters so they could decide for themselves.

There was one problem with that pitch: Massachusetts voters had already decided.

In November 2016, nearly 54% of Massachusetts voters approved Question 4, legalizing adult-use cannabis. Nearly a decade later, the state has developed a multibillion-dollar industry, created thousands of jobs, and generated substantial tax revenue.

Now voters are being asked to reverse much of that decision.

On November 3, Massachusetts voters will decide Question 8, a proposal that would eliminate licensed recreational cannabis sales, roll back home cultivation protections, and dismantle key elements of the state's adult-use regulatory framework.

For Faraone, who has spent more than two decades covering cannabis, politics, and culture in Massachusetts, the repeal effort is more than another confrontation between legalization supporters and prohibitionists.

It's a warning about how quickly political gains can become vulnerable when the people who benefit from them stop paying attention. And the warning extends well beyond Massachusetts.

A Repeal Campaign Is Testing Whether the MA Industry Can Defend It - The Bluntness Photo by Element5 Digital on Unsplash

A $10 Billion Industry on the Ballot

Massachusetts is not debating whether to launch a recreational cannabis market. It's considering whether to dismantle one that already exists.

According to the Massachusetts Cannabis Control Commission (CCC), licensed adult-use businesses surpassed $10 billion in cumulative gross sales in September 2026, less than eight years after the state's first recreational dispensaries opened.

The market generated approximately $1.65 billion in adult-use sales in 2025. By the end of August 2026, sales had reached another $1.09 billion.

The CCC reported approximately 15,000 individual employees working in the industry as of August, along with 782 operating cannabis businesses, including medical dispensaries. More than 100 businesses were identified as equity-owned or operated.

In fiscal year 2026, Massachusetts collected approximately $336 million in state and local cannabis-related taxes, according to the CCC. Since legalization, the industry has generated approximately $2 billion in tax revenue.

Question 8 would put a substantial portion of that economic activity at risk.

Under the proposal, adult-use retail sales would no longer be legal. Adults 21 and older could still possess up to one ounce of marijuana, including no more than five grams of concentrate, but possession of more than one ounce and up to two ounces would trigger a $100 civil penalty and forfeiture. The measure would also eliminate existing statutory protections for home cultivation.

Medical marijuana would remain legal, and existing adult-use operators could apply through an expedited process to become medical dispensaries. However, the measure does not guarantee that recreational businesses could successfully transition into the medical market. The law would take effect January 1, 2028.

That distinction matters. Question 8 would not make every form of adult cannabis possession illegal. It would instead eliminate the regulated commercial system through which most adult consumers currently purchase cannabis.

Repeal advocates argue that legalization has created public health and safety problems, including concerns about high-potency products, impaired driving, addiction, and youth exposure.

Those concerns deserve scrutiny. Cannabis carries real health risks, particularly for adolescents and some vulnerable consumers. But eliminating licensed adult-use retail does not necessarily eliminate cannabis demand.

It raises a different question: whether consumers would shift toward medical access, illicit sellers, or neighboring legal markets, and whether that shift would improve public health outcomes.

Follow the Money: Who Is Behind the Massachusetts Cannabis Repeal Effort? - The BluntnessImage used with permission from Talking Joints Memo

Who Is Behind the Massachusetts Cannabis Repeal Effort?

The organization advancing Question 8 is the Coalition for a Healthy Massachusetts, whose campaign has received overwhelming financial support from SAM Action Inc., an organization affiliated with Smart Approaches to Marijuana (SAM).

SAM is a national organization opposed to commercial marijuana legalization and has been associated with prominent prohibition advocates, including co-founder Kevin Sabet.

According to October campaign finance reporting, approximately $3.48 million of the coalition's first $3.53 million in reported contributions came from SAM Action, roughly 98.5% of its funding.

SAM Action's nonprofit structure means the public cannot necessarily identify the individuals or organizations behind its contributions.

That funding concentration is significant. Whatever the local concerns motivating individual Massachusetts voters, the campaign's financial backing is overwhelmingly connected to a national anti-legalization organization.

But Faraone cautions against assuming the campaign is evidence of a broad public revolt against legal cannabis.

During an interview with The Bluntness, he argued that a meaningful segment of voters has always opposed legalization. The existence of that opposition does not necessarily mean public opinion has fundamentally shifted.

His concern is that organized campaigners can exploit that opposition, combined with ballot initiative rules and industry complacency, to create a political threat that extends far beyond their underlying public support.

Question 8's supporters, meanwhile, say their campaign reflects genuine concerns about how commercial cannabis legalization has developed.

In Just Say No!, which The Bluntness reviewed ahead of its public release, Coalition for a Healthy Massachusetts spokesperson Wendy Wakeman argues that the industry's commercialization, product potency, and public health consequences have exceeded what some voters expected when legalization passed.

Those arguments form the campaign's substantive case for repeal, even as its financing and petition tactics have attracted scrutiny.

A Repeal Campaign Without a Public Mandate?

For all the money and political maneuvering surrounding Question 8, Massachusetts voters appear remarkably uninterested in reversing legalization.

A Suffolk University/Boston Globe poll released October 20 found that 71.4% of likely voters intend to reject the measure, compared with just 21.4% who support it.

A separate University of Massachusetts Amherst/WCVB poll found 61% opposed and 31% in favor.

The opposition is not limited to cannabis consumers or industry stakeholders.

Governor Maura Healey, Senators Elizabeth Warren and Ed Markey, Representative Ayanna Pressley, Boston Mayor Michelle Wu, and more than 50 state lawmakers have publicly come out against Question 8. The coalition includes House Speaker Ronald Mariano and Senate President Karen Spilka.

For Faraone, the numbers reinforce an important distinction: opposition to legalization has always existed, but that doesn't necessarily translate into a growing public appetite for prohibition.

In fact, the latest polling suggests the opposite.

Yet the repeal campaign still succeeded in placing the future of a $10 billion industry before voters.

That may be the most revealing part of the story.

The question is no longer simply whether Massachusetts voters will reject repeal. It's how a campaign with comparatively little public support managed to force an established industry, its workers, and its political allies into defending a decision voters made nearly a decade ago.

The Petition Fight That Became a Legal Battle

One of the most contentious aspects of Question 8 has been the process used to gather the signatures necessary to qualify for the ballot.

In his forthcoming documentary, Faraone chronicles his investigation of petition circulators, the legal challenges that followed, and the cannabis industry's response.

The film includes accounts of petition circulators allegedly describing the measure in ways that obscured its consequences.

Faraone challenges the idea that voters were simply being asked to revisit legalization, pointing out that the proposal would eliminate existing rights and commercial protections established after the 2016 vote.

The repeal campaign disputes allegations of intentional deception.

In an interview featured in the film, Wakeman defended the professional signature-gathering company hired by the coalition, saying collectors were trained and instructed on the campaign's message. She acknowledged the possibility of misunderstandings but denied an intent to defraud voters.

The Massachusetts State Ballot Law Commission dismissed a challenge involving alleged misleading signature collection. A separate legal challenge reached the Massachusetts Supreme Judicial Court.

In Pineau v. Attorney General, decided June 12, 2026, plaintiffs argued that the proposed initiative improperly combined multiple subjects and that the attorney general's summary failed to adequately explain important consequences of the measure, including the elimination of adult-use social equity programs and host community agreement requirements.

The court rejected the challenge, finding that the initiative satisfied the state's constitutional requirements and that the attorney general's summary adequately conveyed the proposal's principal effects.

Importantly, the court's ruling did not adjudicate every allegation about how individual petition circulators described the measure. The Supreme Judicial Court case concerned constitutional certification and the adequacy of the official summary, not a comprehensive factual determination about signature-gathering conduct.

For Faraone, the larger lesson is procedural. By the time an industry recognizes the seriousness of a ballot initiative, organizers may already have gathered the signatures, secured the financing, and established the legal footing necessary to force an election. Challenging the measure afterward can be expensive, time-consuming, and unsuccessful.

Winning the Vote Isn't Enough - Vote No on Question 8 - The BluntnessImage used with permission from Talking Joints Memo

The Cannabis Industry Was Caught Sleeping

Perhaps the most revealing part of Faraone's account is his acknowledgment that even people closely following the Massachusetts cannabis industry initially underestimated the repeal effort.

He recalls that when the campaign first surfaced, Talking Joints Memo was among the earliest publications to report on it. At the time, the effort did not appear particularly formidable.

The assumption was that a state with a mature adult-use market, a history of cannabis reform, and substantial public support for legalization would have little trouble rejecting a proposal to dismantle the system. That assumption proved costly.

In footage from the forthcoming documentary, Faraone visits a gathering of approximately 150 cannabis stakeholders in Framingham, where operators, trade associations, and advocates began organizing against Question 8.

He reports that some participants acknowledged that industry members had dismissed the threat only weeks earlier. By then, the repeal campaign had already established a substantial financial and organizational presence.

During his conversation with The Bluntness, Faraone emphasized that the mechanics of qualifying a ballot initiative can give a disciplined minority a significant advantage over a larger but fragmented opposition.

"The mechanics of qualifying a ballot initiative can give a disciplined minority a significant advantage over a larger but fragmented opposition."

A campaign does not need to persuade a majority of voters before it begins collecting signatures. It needs sufficient organization and resources to satisfy the state's qualification requirements.

Once the question reaches the ballot, the burden shifts to opponents to organize, raise money, educate voters, and defend the existing law.

For an industry accustomed to competing over shelf space, wholesale pricing, retail margins, and market share, that requires an entirely different kind of coordination.

Faraone's advice to operators in other states is straightforward:

• identify threats early,
• retain knowledgeable election counsel,
• work with established reform organizations, and
• don't assume a repeal campaign will collapse under the weight of its own arguments.

Organizations such as NORML and the Marijuana Policy Project can offer experience, but local businesses, consumers, and community advocates still need to mobilize.

The industry cannot outsource its political survival.

Legalization's Imperfections Are Not Necessarily a Case for Repeal

Ten years after voters approved legalization, the cannabis industry has not fulfilled every promise made during the campaign.

The economic stakes are becoming increasingly personal for the businesses and communities that have built livelihoods around Massachusetts' legal cannabis market.

In a recent episode of his High Functioning podcast, Good Feels founder Jason Reposa spoke with Nick Lazaro, a small-business owner, Millbury Select Board member, and candidate for state representative in the 7th Worcester District.

Lazaro, who opposes Question 8, argued that the consequences would extend beyond dispensary owners to employees working in cultivation, manufacturing, retail, operations, and quality control.

For Reposa, those concerns are grounded in the experience of operating a licensed cannabis business.

He recalled that Good Feels initially paid approximately $2,000 per month for banking services before negotiating a lower rate, illustrating the additional costs cannabis companies face because of federal prohibition. Advertising restrictions and other compliance requirements add further complications.

"It's like playing startup in hard mode," Reposa said.

The irony is difficult to ignore. Massachusetts entrepreneurs have spent years investing in facilities, employees, compliance systems, and businesses designed to operate within the state's legal framework.

Now they are being asked to defend the continued existence of that framework.

Lazaro also raised concerns about the complexity of the ballot itself. With numerous questions facing voters, he argued that even politically engaged residents may struggle to understand the implications of each proposal.

That concern echoes a central theme of Faraone's investigation: whether voters fully understand the distinction between regulating an imperfect cannabis industry and eliminating adult-use retail altogether.

Social equity programs have encountered obstacles. Independent operators face intense competition. Worker protections and business sustainability remain ongoing concerns. The regulated marketplace is far from perfect.

Those shortcomings deserve serious attention. But Faraone challenges the suggestion that imperfections in legalization justify returning adult-use sales to the illicit market.

His argument is that Massachusetts is still developing a relatively young industry. Regulatory systems, worker protections, and equity programs can be improved through legislation, enforcement, and market reform.

The unregulated market offers no comparable framework for systematically improving product testing, workplace standards, or economic opportunity.

Question 8 would also affect programs intended to address the harms of past cannabis prohibition.

In its September economic update, the CCC reported that nearly $60 million in financial assistance had been provided to equity licensees since 2024 through the Cannabis Social Equity Trust Fund.

The Supreme Judicial Court's decision in Pineau confirms that the initiative would repeal statutory provisions establishing the adult-use social equity program and related trust framework.

That creates a particularly difficult contradiction.

Massachusetts encouraged entrepreneurs, including people from communities disproportionately affected by prohibition, to participate in a legal industry. Some invested substantial capital, secured licenses, hired employees, and built businesses around that opportunity.

Now the state is considering eliminating the market those entrepreneurs were encouraged to enter.

Whatever voters think about cannabis commercialization, those consequences deserve a place in the debate.

From Competitors to Coalition

For all the industry's initial complacency, the repeal effort has also produced something Massachusetts cannabis operators have often struggled to achieve: cooperation.

Faraone's forthcoming documentary captures businesses and advocates coming together across competitive boundaries.

One example is a collaborative preroll initiative involving multiple Massachusetts cultivators, organized around raising awareness and supporting the campaign against repeal. Another is a cannabis walk organized by Haverhill-area businesses to engage local communities.

These efforts may appear modest compared with multimillion-dollar campaign contributions, but they represent an important shift.

The operators involved are not simply defending individual businesses. They're defending the legitimacy of an entire regulated marketplace.

And they are discovering that competitors with different business models, ownership structures, and commercial interests share a common political vulnerability.

A cultivator, a retailer, a delivery operator, and a social equity licensee may disagree about pricing, regulation, or market concentration. But those disagreements become secondary when the continued existence of their market is on the ballot.

The question is whether that cooperation survives after Election Day.

Could Massachusetts Become a Blueprint for Cannabis Repeal Elsewhere?

Faraone is not convinced that Question 8 represents an unstoppable national movement against legalization.

He sees the Massachusetts campaign as part of a broader pattern of organized opposition operating within the particular political and procedural opportunities available in individual states.

In his interview, he pointed to Maine and Arizona as other states worth examining, while emphasizing that each state's ballot rules, political culture, and cannabis market create different conditions.

Maine, in particular, deserves attention because its petition process differs from Massachusetts', potentially giving organizers a different timeline for building campaigns.

The larger concern is not that every legal state is equally vulnerable. It's that an unsuccessful repeal campaign can still impose substantial costs on the industry it targets.

Businesses must divert money, leadership attention, and organizational resources toward defending rights and licenses they believed were already settled.

Even if the repeal effort loses, it can disrupt normal operations and force the industry to fight on terrain chosen by its opponents.

Legalization is not a permanent political guarantee. It is a statutory and regulatory system that can be challenged through the same democratic mechanisms that created it.

MA dispensary workers showing their opposition to the repeal campaignImage courtesy of Talking Joints Memo

Winning the Vote Isn't Enough

With multiple polls showing overwhelming opposition to Question 8 and a growing coalition of elected officials urging its defeat, Massachusetts' regulated cannabis market appears likely to survive November 3.

But Faraone argues that the margin matters.

A narrow defeat could encourage repeal organizers to regroup, refine their approach, and look for more favorable conditions elsewhere. A decisive rejection could make Massachusetts a much less attractive model for future campaigns.

Even so, the industry should resist the temptation to interpret a victory as proof that the threat was never serious.

Question 8 has already demonstrated that legalization does not make an industry politically invulnerable. A sufficiently organized and financed campaign can force businesses to spend time, money, and political capital defending laws they assumed were settled.

The real test may come after Election Day.

Will the cooperation forged between competing operators, grassroots advocates, and political leaders survive once the immediate threat disappears? Or will the industry return to business as usual until the next petition circulator appears outside a supermarket?

Massachusetts voters may be preparing to deliver a decisive answer on repeal.

Whether the cannabis industry has learned anything from the experience is another question.

A Personal Note from the Publisher

Legalization was never just about selling weed. It was about ending a failed policy, protecting personal freedom, and creating opportunities for people who spent decades fighting for the right to participate in this industry.

Massachusetts helped lead that change. And while the legal cannabis market is far from perfect, the answer isn't to dismantle it. It's to make it better.

Progress is hard won. It's also easier to undo than most people realize.

If you're reading this and you live in Massachusetts, vote NO on Question 8 on November 3.

Don't let a decade of progress go up in smoke.

New York cannabis knows how to put on a show.

At September's Revelry Buyers' Club, Pier 36 was buzzing with brands, buyers, cultivators, entrepreneurs, and industry hopefuls looking to stake their claim in one of the country's most exciting cannabis markets.

There were elaborate booths, innovative products, eye-catching packaging, celebrity-backed brands, and plenty of networking. The energy was unmistakable.

New York cannabis has arrived. And everybody wants in.

But spend enough time at these gatherings, then spend a few days visiting actual dispensaries, and a different picture begins to emerge.

Behind the polished presentations and sophisticated branding is a less glamorous conversation about wholesale pricing, retail margins, promotional allowances, payment terms, and who can afford to keep competing.

I've experienced that disconnect firsthand through my work representing cannabis brands across flower, pre-rolls, vapes, and edibles, including Empire Standard, Dada Exotics, and SpacePoppers. I've negotiated with dispensary buyers, worked alongside retail teams, helped develop promotions, and watched what happens after the excitement of a product launch wears off.

Increasingly, the conversation comes back to price.

The trade-show floor celebrates differentiation. The dispensary floor often rewards whoever can deliver the better deal.

With Hall of Flowers returning to New York on October 21 and 22, it's worth asking whether all this industry excitement is translating into sustainable businesses or accelerating a race to the bottom.

Because the latest market data reveals a paradox that should concern everyone building a cannabis business in New York.

The industry is growing. Consumers are buying more legal cannabis. Yet average selling prices are declining, commercial success is unevenly distributed, and hundreds of brands are competing for consumer attention.

The question is no longer simply how big New York cannabis can become.

It's who can build a sustainable business within it.

The Billion-Dollar Market With a Pricing Problem

Let's start with the good news.

New York's legal cannabis market continues to expand rapidly.

According to a September 16 analysis by New York 420 Week, licensed dispensaries generated an estimated $1.212 billion in sales across 34.4 million units between January 1 and September 15, 2026.

The study, drawing on third-party retail sell-through estimates covering 634 dispensaries, found that average daily sales increased 29.9% between January and August.

But here's the catch.

Over that same period, the number of units sold per day increased 39.4%, while the average price per item fell 6.8%, from $36.82 in January to $34.33 in August.

The average price declined every month.

Read those numbers together. New York is selling substantially more cannabis, but generating less revenue per average item sold.

That's not necessarily a bad thing for consumers. Lower prices can make legal cannabis more accessible, improve competition with unlicensed sellers, and encourage participation in the regulated market.

Nor does a declining average item price automatically establish that retailers or brands are experiencing shrinking profit margins. Changes in product mix, package sizes, and consumer preferences can also influence average selling prices.

But the commercial challenge is clear.

When unit volume grows faster than revenue, businesses must continually examine whether that additional volume is translating into sustainable profit.

"Selling more products isn't necessarily the same as making more money."

And there's another finding in the research that challenges the industry's growing fixation on price.

The Biggest Dispensaries Aren't Selling the Cheapest Cannabis

One of the most revealing findings in New York 420 Week's analysis is the relationship between dispensary sales performance and average item prices.

The state's 10 highest-revenue dispensaries sold products at an average of $41.62 per item during the study period.

The bottom 284 dispensaries averaged just $30.88.

That's a difference of approximately 35%.

And the pattern extends across the rankings.

Stores ranked 11 through 50 averaged $37.30 per item. Those ranked 51 through 150 averaged $34.59. Stores ranked 151 through 350 averaged $33.64.

Research from New York 420 Week - https://newyork420week.com© 2026 New York 420 Week

In other words, average item prices declined consistently as store revenue rankings declined.

This doesn't mean the largest dispensaries are charging more for identical products. They may carry different assortments, serve different customer demographics, or generate greater sales of premium categories.

Nor does the relationship establish that higher prices cause better retail performance.

But it challenges a persistent assumption in cannabis retail: that lowering prices is the most reliable way to increase sales.

The highest-grossing dispensaries are selling a higher-priced mix of products, not the cheapest assortment in the market.

Meanwhile, approximately 43% of the dispensaries included in the study generated less than $1 million in estimated sales during the reporting period.

That's not proof those businesses are unprofitable, particularly since stores opened at different times.

But it illustrates how unevenly the market's growth is being distributed.

There's another important counterexample in Ulster County.

Research from New York 420 Week - https://newyork420week.com© 2026 New York 420 Week

During comparable reporting windows in 2026, average daily cannabis sales in Ulster County increased 84.8% while average item prices remained essentially unchanged.

Even among the nine dispensaries already operating at the beginning of the year, sales increased 53.6%.

The takeaway isn't that higher prices are always better or that discounting never works.

It's that growth and declining prices don't have to go hand in hand.

And in an industry increasingly obsessed with pricing concessions, that distinction deserves serious attention.

Everybody Wants a Piece of New York

Revelry Buyers' Club has become an important gathering place for New York's cannabis community.

Produced by On The Revel, the event has helped connect the cultivators, entrepreneurs, advocates, retailers, and cultural voices working to establish the state's legal industry.

That contribution deserves recognition.

New York didn't invent cannabis culture, nor should it pretend to own it.

California's Emerald Triangle cultivators, legacy growers, and cannabis pioneers helped establish much of the agricultural craftsmanship, genetics, and knowledge that shaped modern cannabis.

But New York has its own extraordinary cultural influence.

Hip-hop, fashion, art, music, street culture, and generations of underground entrepreneurs helped make cannabis part of the city's identity long before the first licensed dispensary opened.

New York's legalization opportunity was never supposed to be about simply replicating the markets that came before it.

It was an opportunity to build something distinctive, rooted in the state's culture, communities, entrepreneurs, and history.

That's what makes the latest wave of industry attention both exciting and concerning.

September's Revelry gathering featured New York microbusinesses alongside established national brands, including Cookies, STIIIZY, and Wyld, according to Cannabis Now. GreenState's coverage highlighted the New York debut of Los Angeles-based Wizard Trees.

And Hall of Flowers is preparing to bring another wave of brands, buyers, investors, and industry professionals to the city later this month.

There's nothing inherently wrong with national brands entering New York.

Experienced operators can introduce quality products, professionalize distribution, create jobs, and raise competitive standards.

Nor should New York brands be insulated from competition simply because they arrived first.

But let's acknowledge the economic reality.

Many independent cultivators, microbusinesses, and social equity entrepreneurs are now competing with companies that possess greater resources, established consumer recognition, larger production capacity, and experience navigating mature cannabis markets.

Some can afford to invest heavily in distribution, promotional support, and market development.

Others cannot.

And when price becomes the primary consideration, those differences matter.

The challenge isn't that outside brands are entering New York.

It's whether the market is creating enough value for the independent businesses that helped establish it to compete sustainably.

More Brands, More Competition, But Not Necessarily More Opportunity

New York certainly isn't suffering from a lack of brands.

- YouTube © 2026 New York 420 Week

The September 16 New York 420 Week study identified 1,188 brands competing across the state's licensed cannabis market.

Yet the largest brand accounted for only 4.1% of brand-attributed sales.

On the retail side, the top 10 dispensaries generated approximately 15.4% of estimated statewide sales.

Those figures tell an important story.

New York remains a highly fragmented market. No single brand or retailer controls anything close to a dominant statewide share.

Source: Lit Alerts NY market data, Jan 1 – Sep 17, 2026 · Sour Cat analysisMenu-sampling estimates, not point-of-sale data.© 2026 New York 420 Week

That creates opportunities for new entrants.

But it also creates an intensely competitive environment in which hundreds of businesses are fighting for attention, shelf space, and repeat purchases.

And getting into a dispensary is only the beginning.

A brand can secure an initial order through aggressive wholesale pricing or a compelling sales presentation.

But what happens afterward?

Does the product sell through?

Do consumers return for it?

Can the retailer maintain its margins?

Can the brand sustain its economics once introductory promotions end?

Or does the product sit on the shelf until the next discount moves it?

These are the questions that determine whether distribution becomes a sustainable business or simply another expensive exercise in buying market share.

"Distribution is not demand. Shelf space is not loyalty. And revenue is not profitability."

Yet an industry obsessed with expanding its retail footprint can easily confuse all three.

The Trade Show Is Not the Store

Here's where the industry needs a reality check.

At events like Revelry, conversations revolve around innovation, genetics, quality, cultivation, craftsmanship, branding, and differentiation.

Back at the dispensary, those conversations frequently turn to wholesale cost, retail margins, promotional support, payment terms, and whether another brand can offer a better deal.

I've experienced that dynamic firsthand.

Through my work representing Empire Standard, Dada Exotics, and SpacePoppers, I've negotiated with buyers across New York and worked closely with dispensary owners, inventory managers, and budtenders.

I've seen how difficult it can be to sell a genuinely differentiated product when the immediate comparison is what another brand is willing to offer for less.

And I've watched how quickly the conversation can shift from product quality and consumer appeal to pricing concessions and promotional allowances.

None of those considerations are unreasonable.

Retailers have rent to pay, employees to support, inventory to manage, and customers who are increasingly price-conscious.

They need products that sell, and they need healthy margins.

But when price becomes the dominant consideration, something important gets lost.

Brands begin competing primarily on wholesale cost rather than consumer preference.

Retailers become conditioned to expect promotional concessions.

Consumers may become accustomed to buying on promotion rather than developing loyalty to a particular product.

And businesses find themselves working harder to sustain increasingly challenging economics.

That cycle is particularly difficult for smaller operators.

A well-capitalized company may be able to absorb temporary losses or invest heavily in promotions while expanding distribution.

An independent cultivator or emerging brand may not have that luxury.

The irony is that many of these businesses invest heavily in cultivation, product development, packaging, and brand building, only to compete on the one variable that can undermine their ability to recover those investments: Price.

"A packed booth doesn't guarantee sell-through. Distribution doesn't guarantee demand. And a discount doesn't create brand loyalty."

Those distinctions should be obvious.

But they're too often overlooked in an industry that celebrates how many doors a brand enters rather than how sustainably its products perform once they're there.

McDonald's Just Offered Cannabis a Warning

Interestingly, one of the clearest recent examples of discounting's limitations comes from outside cannabis.

In an October 12 Inc. Magazine article, Kimanzi Constable examined McDonald's efforts to stimulate sales through value meals, promotional campaigns, and discount-driven offers.

Despite those initiatives, McDonald's U.S. comparable sales increased just 0.8% in the second quarter of 2026, compared with 3.9% in the previous quarter.

McDonald's hasn't abandoned affordability, nor does that slowdown prove discounts caused weaker performance.

But its experience raises a familiar business question.

What happens when promotions become a substitute for creating a compelling customer experience and demonstrating product value?

McDonald's has spent decades building one of the world's most recognizable brands, with enormous purchasing power, sophisticated operations, and global scale.

Yet even a business with those advantages must balance affordability, customer experience, product innovation, and profitability.

Now consider the challenge facing an independent New York cannabis cultivator or single-store dispensary.

If a global fast-food giant cannot rely on discounting alone to drive sustainable growth, why would an emerging cannabis business with significantly fewer resources build its competitive strategy primarily around lower prices?

The lesson isn't that discounts are bad.

It's that discounting is a tactic, not a business model.

And when price becomes the primary reason customers choose one product over another, businesses risk weakening the differentiation that makes their brands valuable.

Premium Cannabis Isn't Dead. Differentiation Still Works.

Despite declining average item prices, New York consumers are not universally choosing the cheapest cannabis available.

The market data suggests that successful businesses can compete across a broad range of price points.

New York 420 Week's Manhattan market analysis estimated that Fernway generated approximately $7.7 million in sales at an average item price of $63.39.

Meanwhile, ayrloom generated approximately $9.3 million at an average item price of $25.87.

Both ranked among Manhattan's leading brands.

Manhattan Cannabis Is a Commuter Market, Not a Local One - New York 420 Week© 2026 New York 420 Week

Those aren't like-for-like price comparisons. The companies sell different product assortments, and average item prices don't establish profitability.

But the figures illustrate an important point.

There is room for different value propositions.

The same applies to New York's smaller operators.

A separate New York 420 Week analysis estimated that microbusiness brands generated approximately $46.5 million in own-brand sales through September 23, representing roughly 4% of the branded market covered by its research.

Their average item price was $36.71, compared with $35.83 across all brands.

The Best-Performing Cannabis Micros in New York - New York 420 Week© 2026 New York 420 Week

That doesn't mean every microbusiness can command a premium or that smaller operators are insulated from competitive pressure.

But it challenges the assumption that emerging brands can only compete by being cheaper.

Consumers still respond to quality, consistency, product experience, brand recognition, and trust.

The opportunity to differentiate exists.

The question is whether brands and retailers are doing enough to capitalize on it.

New York Doesn't Just Have a Pricing Problem. It Has a Merchandising Problem.

Walk into a typical New York dispensary and you'll often encounter an enormous assortment of products organized by category, brand, THC percentage, and price.

Flower. Pre-rolls. Vapes. Edibles.

Dozens of brands. Hundreds of SKUs.

And an online menu that can feel more like scrolling through a wholesale inventory database than shopping in a thoughtfully designed retail environment.

For experienced consumers who know exactly what they want, that may be sufficient.

For everyone else, it creates unnecessary friction.

What makes one eighth worth $25 and another worth $50?

Why should a consumer choose one cultivar over another?

What distinguishes a particular brand beyond its packaging, THC percentage, or promotional price?

When retailers don't answer those questions effectively, consumers default to the easiest available comparison: Price.

This is where cannabis has an enormous opportunity to learn from sophisticated specialty retailers.

Consider Sephora.

Beauty products, like cannabis, involve personal preferences, unfamiliar ingredients, product discovery, education, premiumization, and considerable variation in quality and price.

Sephora doesn't build its entire shopping experience around whichever brand offers the deepest discount.

It invests in merchandising, curated product discovery, staff expertise, and helping consumers understand why products differ.

Cannabis retailers should be thinking the same way.

And the market data reinforces why.

According to New York 420 Week's September 16 analysis, pre-rolls accounted for 31.2% of units sold but only 20.1% of sales value.

Flower represented 21.4% of units but generated 33.2% of sales value.

Vaporizers accounted for 19.1% of units and 28.4% of sales value.

Different product categories serve different commercial roles.

Pre-rolls are the most frequently purchased thing in New York — nearly a third of all units — and they generate a fifth of the money. New York 420 Week© 2026 New York 420 Week

A retailer focused exclusively on moving the greatest number of units or stocking the lowest-priced products may be overlooking opportunities to improve assortment productivity and revenue mix.

That doesn't mean prioritizing expensive products indiscriminately. Gross margins, inventory turnover, customer demand, and repeat purchases all matter.

But it demonstrates why sophisticated retailing requires more than simply filling shelves and offering discounts.

Instead of making customers navigate hundreds of largely undifferentiated SKUs, organize assortments around meaningful consumer preferences.

Build clear good-better-best price and quality tiers.

Give budtenders the training and product knowledge to explain cultivation methods, genetics, freshness, product formats, and quality differences.

Use sell-through data, repeat purchasing, and inventory productivity to identify products that actually deserve shelf space.

And create online menus that help consumers discover products rather than simply search through inventory.

New York's cannabis regulations impose important restrictions on advertising, promotional practices, and product claims. Retailers must operate within those rules, without making unsupported health or therapeutic claims.

But those constraints make thoughtful merchandising more important, not less.

"Stop making customers shop your inventory. Start merchandising their decisions."

That's how retailers can create value beyond price.

And that's how brands can begin earning consumer preference rather than continually purchasing shelf space through concessions.

The Equity Promise Is Being Tested

There's another dimension to this conversation that deserves attention.

New York's cannabis legalization framework was designed partly to address the economic consequences of prohibition and create opportunities for communities historically excluded from the legal industry.

Social equity entrepreneurs, legacy operators, independent cultivators, and small businesses were supposed to have a meaningful opportunity to participate.

But participation and long-term economic viability are two different things.

A microbusiness may produce exceptional flower but lack the resources to support aggressive wholesale discounts.

An independent brand may have a loyal following but struggle to compete with larger operators offering extensive promotional support or favorable payment terms.

A single-store dispensary may deliver outstanding service but lack the purchasing leverage of a growing retail chain.

These disadvantages don't make competition inherently unfair.

But they raise important questions about whether the market's evolving economics align with legalization's original objectives.

New York doesn't need to protect every business from competitive pressure.

It does need to recognize that an industry increasingly dependent on scale, promotional spending, and financial endurance could undermine the opportunities it was designed to create.

The danger isn't simply that some businesses will fail.

That's an unavoidable part of any emerging market.

The danger is that New York could gradually lose the independent cultivators, entrepreneurs, and culturally rooted brands that make its cannabis economy distinctive.

And replace them with an increasingly interchangeable assortment of products competing primarily on price.

That's not an especially compelling vision for the future of New York cannabis.

Hall of Flowers Should Be About More Than the Next Big Drop

When Hall of Flowers returns to Pier 36 later this month, there will undoubtedly be another impressive display of cannabis entrepreneurship.

Expect innovative products, ambitious founders, sophisticated packaging, and plenty of conversations about expansion and distribution.

All of that deserves recognition.

But I'd like to see a different set of questions become just as important as who's launching what.

• Which brands are generating sustainable repeat purchases?
• Which retailers are increasing gross profit rather than simply chasing topline revenue?
• Which products are selling because consumers genuinely prefer them, rather than because they're discounted?
• Which dispensaries are creating shopping experiences that encourage discovery, build trust, and support long-term loyalty?
• And perhaps most importantly, which independent operators are building businesses that can still thrive five years from now?

Those questions are harder to answer than how many dispensaries carry a particular brand or how much revenue the market generated last quarter.

They're also far more consequential.

Revelry reminded us how much talent, creativity, ambition, and cultural energy exist in New York cannabis.

Hall of Flowers will undoubtedly reinforce that impression.

But the industry's future won't be determined by the size of its trade-show booths, the lines at product activations, or the number of purchase orders written during an event.

It will be determined in dispensaries, where consumers make purchasing decisions, retailers manage inventory, and brands either earn repeat business or disappear into the discount bin.

New York cannabis has already demonstrated that it knows how to generate excitement.

The sales figures demonstrate that consumer demand is real.

But demand alone isn't enough.

The next phase of New York cannabis won't be won simply by whoever sells the most products at the lowest price. It will be won by businesses that give consumers compelling reasons to choose them, return, and pay for the value they deliver.

And that starts with a fundamental shift in thinking.

"Stop making customers shop your inventory. Start merchandising their decisions."

Editor's note: Harrison Wise has worked in New York cannabis wholesale sales and brand representation, including with Empire Standard, Dada Exotics, and SpacePoppers. His observations draw partly on that firsthand experience. Market figures attributed to New York 420 Week & Lit Alerts include third-party estimated retail sales and are not audited financial results.